A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
← catalyst calendarNCT06810505 · readout ≤ 1,684 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
420estimated
Sites
64
Countries
Canada, Denmark, Hungary +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-13 | actual | When the study began enrolling |
| Primary completion | Mar 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Migraine
Interventions
- Drug: Atogepant — also filed as Qulipta, Aquipta
- Drug: Placebo for Atogepant
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events (AEs)
measured Up to approximately 16 weeks
Change From Baseline in Mean Monthly Migraine Days
measured Baseline (Week 0) through Week 12
Publications
- PMID 41235617 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed